Exenatide News and Research

RSS
Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.
Diabetes drug could help with smoking cessation

Diabetes drug could help with smoking cessation

Insulin resistance largely undetected in non-diabetic patients with Parkinson's disease

Insulin resistance largely undetected in non-diabetic patients with Parkinson's disease

Exenatide treatment improves depression symptoms in PD patients

Exenatide treatment improves depression symptoms in PD patients

Study shows link between Parkinson’s and type 2 diabetes

Study shows link between Parkinson’s and type 2 diabetes

Hacking 'drug trafficking' system could increase effectiveness of diabetes treatment

Hacking 'drug trafficking' system could increase effectiveness of diabetes treatment

Chemist finds how to control blood sugar without usual side effects

Chemist finds how to control blood sugar without usual side effects

Diabetes patients least likely to follow medical advice regarding medication due to side effects

Diabetes patients least likely to follow medical advice regarding medication due to side effects

Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

GLP-1 receptor agonist may benefit high-risk diabetes

GLP-1 receptor agonist may benefit high-risk diabetes

New clinical trial focuses on respiratory drug ambroxol for treatment of Parkinson's disease

New clinical trial focuses on respiratory drug ambroxol for treatment of Parkinson's disease

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

Columbia University data scientists create world's first catalog of therapeutic venom

Columbia University data scientists create world's first catalog of therapeutic venom

Oral formulation of insulin shows promise in management of blood glucose in diabetic rats

Oral formulation of insulin shows promise in management of blood glucose in diabetic rats

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Study shows how GLP-1 receptor agonists modify the brain's response to food

Study shows how GLP-1 receptor agonists modify the brain's response to food

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Patients with Parkinson's disease show improvements after exenatide therapy

Patients with Parkinson's disease show improvements after exenatide therapy